Alteration of serum levels of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL) after treatment in the Helicobacter pylori-positive gastric ulcer.

Background: This study aimed to explore the clinical efficacy of probiotics plus quadruple therapy on Serum levels of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL) in treating Helicobacter pylori (Hp)-positive gastric ulcer (GU). Methods: One hundred and twenty-four patients with Hp-positive GU treated in our hospital from January 2021 to January 2024 were randomly separated into control and observation groups. The former received conventional quadruple therapy, and the latter received tetralogy of viable bifidobacterium tablets combined with conventional quadruple therapy. The clinical efficacy, Hp eradication rate, levels of inflammatory cytokines and gastrointestinal hormone, incidence of adverse reactions, and quality of life were compared in 2 groups. Results: The total effective rate of the observation group was 96.77%, higher than that of the control group (82.25%). The Hp eradication rate in the observation group was higher than in the control group. After therapy, IL-6, TNF-a and CRP levels declined in 2 groups, and those in the observation group presented lower compared to the control group. After therapy, MLT level was elevated while GAS level was declined in 2 groups, and the improvements of MLT and GAS levels in the observation group were more significant than those in the control group. The incidence of diarrhoea in the observation group was lower than that in the control group, and there was no difference in the incidence of nausea and abdominal distension between 2 groups. Conclusions: This study investigated the effects of probiotics combined with quadruple therapy on serum levels of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS), and motilin (MTL) in patients with Helicobacter pylori (Hp)-positive gastric ulcer (GU). The results demonstrated that this combined treatment approach significantly improved Hp eradication rates, reduced inflammatory cytokine levels, and regulated gastrointestinal hormone secretion. Furthermore, patients receiving probiotics with quadruple therapy experienced better maintenance of intestinal flora balance and enhanced overall quality of life than those receiving conventional quadruple therapy alone. These findings suggest that integrating probiotics into standard treatment protocols for Hp-positive GU may offer a safer and more effective therapeutic strategy, addressing inflammation control and gastrointestinal health while improving patient outcomes.